The current strategy of Bionor is to further advance Vacc-4x in clinical development to develop a functional cure for HIV.
Bionor Pharma AS announced on 16.11.2016 that all preparatory activities of the planned clinical program are on hold and that
the company has initiated a strategic review of Vacc-4x, and the clinical development plan is up to date going forward. Bionor
has engaged a group of highly experienced international HIV scientific, clinical and commercial experts in a strategic partnership
assessment. This process is currently ongoing and is done in close collaboration with the company.